Roche Holding Ltd · SIX:RO
Roche — Investor Day (May 2024)
91 slides from Roche's investor day presentation, May 22, 2024
Slide 1: Roche
Slide 2: Roche Diagnostics Day 2024
Roche Diagnostics Day 2024 London, 22 May 2024
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 4: Opening remarks
Opening remarks Bruno Eschli Head of Investor Relations
Slide 5: Agenda
Agenda Opening remarks 13:00 BST Bruno Eschli, Head of Investor Relations Diagnostics strategy Matt Sause, CEO Roche Diagnostics Roche Diagnostics Solutions: Assay menu in late-stage development Palani Kumaresan, Global Head of Roche Diagnostics Solutions Serum Work Area Systems: The future of the C
Slide 6: Diagnostics contributing to the overall Group success
Diagnostics contributing to the overall Group success COVID-19 testing sales washed out and integration of FMI and Diabetes Care Realizing synergies in Diagnostics and the Group Diagnostics sales and margin development 2019-23 Shift of FMI from Pharma to Diagnostics Division Core OP CHF bn +7% CAGR
Slide 7: Pharma pipeline evolution in the last three quarters
Pharma pipeline evolution in the last three quarters Portfolio shaping ongoing: Focus on high-impact projects led to termination of 20% of total NMEs since Q2 23 NME changes since Q2 23 siRNA targeting AGT in hypertension NMEs added +13 8 -8 -3 Oncology / Hematology +5 (2) 81 4 1 Immunology +2 (1) -
Slide 8: Key growth drivers beyond 2025
Key growth drivers beyond 2025 Many opportunities with significant market potential in both divisions Pharmaceuticals Diagnostics NME Indication Newsflow Timing Product Description Launch tiragolumab NSCLC Final Ph III data H2 2024 Total solution for clinical mass i601 mass spec 2024 spectrometry an
Slide 9: Diagnostics business operating in four customer areas
Diagnostics business operating in four customer areas Delivering innovation across the continuum of care Sales by customer area: Q1 2024 Key updates today ~55% of • cobas® pro / pure Core Lab Diagnostics • cobas® ISE neo / c703 analytical unit sales • Mass spectrometry ~18% of • cobas® 6800 / 8800 v
Slide 10: Diagnostics strategy
Diagnostics strategy Matt Sause CEO Roche Diagnostics Division
Slide 11: Global market leader in in vitro diagnostics
Global market leader in in vitro diagnostics1 #1 39,000+ #1 Market share / Employees share growth2 worldwide R&D investor in IVD CHF 14.1bn 150+ >29 billion Sales in 2023 Country presence Tests performed in 2023 IVD market excludes Diabetes care (BGM, CGM, IDS), NGS, qPCR/NAP, custom biotech and oth
Slide 12: Roche Diagnostics strategy
Roche Diagnostics strategy Driving continued and sustainable success Improve care along DISEASE MANAGEMENT patient journeys SOLUTIONS Outcomes Enable confident healthcare HEALTHCARE DECISION Costs decisions SUPPORT SOLUTIONS Deliver medical value on DIAGNOSTICS SOLUTIONS integrated testing solutions
Slide 13: Our goals as Roche Diagnostics
Our goals as Roche Diagnostics Impact for patients, society and our business Expand our #1 Invest to become a Differentiate through Enable disease position in the leader in decentralized comprehensive solutions management for better clinical laboratory testing across highest burden patient outcomes
Slide 14: Diagnostics Division financial ambition
Diagnostics Division financial ambition Strong sales growth with margin improvement expected, driven by existing business and emerging opportunities Growth and profit drivers ● Continued strong on-market portfolio growth ● Continued business expansion in major and growth markets ● Future product gro
Slide 15: Maintain and expand our #1 position in the clinical laboratory
Deliver medical value on integrated testing solutions Maintain and expand our #1 position in the clinical laboratory Invest to become a leader in decentralized testing Enable confident healthcare decisions Deliver medical value on integrated testing solutions 15
Slide 16: Roche Diagnostics system pipeline
Roche Diagnostics system pipeline Delivering a comprehensive pipeline that enables us achieve our goals Continue to deliver Disrupt the market with Invest to become a leader in in areas of strength transformative innovations decentralized testing Core Lab cobas® cobas® c Next gen blood cobas® b101 n
Slide 17: Roche Diagnostics digital laboratory solutions pipeline
Roche Diagnostics digital laboratory solutions pipeline A strong diagnostics insights portfolio with 5 new products coming to market over the next three years On market In development navify® Lab Operations navify® Analytics for Core Lab navify® POC Operations Diagnostics ● ● navify® Service Intelli
Slide 18: Differentiate through comprehensive solutions across highest burden disease areas
Differentiate through comprehensive solutions across highest burden disease areas Enable confident healthcare decisions Deliver medical value on integrated testing solutions 18 18
Slide 19: Addressing disease areas with highest burden
Addressing disease areas with highest burden A broad menu of diagnostics solutions that will change the standard of care Increasing healthcare & social burden Medical value solutions Cardiometabolic that are differentiated, based on clinical evidence and improve the standard of care Oncology Menu co
Slide 20: Roche Diagnostics test pipeline
Roche Diagnostics test pipeline ~125 new tests launching over the next three years Pipeline Highlights (not exhaustive) Cardio new biomarker CAD metabolic 1 cobas® Sense: TnT-hs TnT-hs Gen 6 LP(a) Oncology 24 CA242, CA50, PG I, PG II in China Kappa Lambda mRNA FoundationOne RNA Amyloid Plasma Panel
Slide 21: Roche Diagnostics digital clinical solutions pipeline
Roche Diagnostics digital clinical solutions pipeline Expanding our existing digital portfolio with 10 new solutions over the next three years On market In development ● Accu-Chek SmartGuide + ● CAD-1 chest pain triage Cardio- Accu-Chek SmartGuide (algorithm) ● Accu Chek Care Predictive apps (CGM) ●
Slide 22: Enable disease management for better patient outcomes
Enable disease management for better patient outcomes Improve care along patient journeys Enable confident healthcare decisions Deliver medical value on integrated testing solutions 22 22
Slide 23: Enabling disease management
Enabling disease management The Accu-Chek portfolio as a first step into home care and remote patient management 23 23
Slide 24: Roche setting new standards for IVD and Healthcare
Roche setting new standards for IVD and Healthcare We are the IVD industry We are delivering We will enhance the leader with a clear innovative solutions to impact of our products strategy to grow above the largest healthcare with digital and AI the market challenges in society powered solutions 24
Slide 25: Roche Diagnostics Solutions: Assay menu in late-stage development
Roche Diagnostics Solutions Assay menu in late-stage development Palani Kumaresan Global Head of Roche Diagnostics Solutions
Slide 26: Disease burden and economic impact
Disease burden and economic impact As the aging population continues to grow, healthcare systems face an escalating burden Number of people above 60 years old 2020-20401 Causes of death globally (millions deaths)2 2040 2020 2030 2040 Cardiometabolic 19 Number 60+ 2030 ~1.8bn Oncology 15 Number 60+ ~
Slide 27: Strategy around menu expansion
Strategy around menu expansion Broadest menu and most differentiated medical value solutions Broad menu on our instruments Medical Value/ Smart gap fills innovative solutions Cardiometabolic Oncology Infectious Neurology diseases Addressing top disease burden globally and allowing customers to conso
Slide 28: Menu overview
Menu overview Largest test menu and strong pipeline with ~125 new tests in the next three years On-market menu and menu expansion (2024-26) Select examples Cardiometabolic: cobas sense hsTroponin-T Next 3 years Today 40 + Oncology: Kappa Lambda dual ISH mRNA >600 New tests Neurology: Elecsys Amyloid
Slide 29: Cardiometabolic pipeline
Cardiometabolic pipeline Continue IVD leadership by further improving cardiometabolic diseases management Focus indications Key Differentiators not exhaustive Coronary artery Chronic kidney Heart failure Diabetes disease disease Early research Lp(a) • CAD next generation solutions to improve the act
Slide 30: Neurology pipeline
Neurology pipeline Lead Neurology diagnostic landscape in targeted indications with high unmet need Focus indications Key Differentiators not exhaustive Alzheimer’s Multiple sclerosis Others Disease • Alzheimer’s Disease: Launch of clinically validated, blood Elecsys Amyloid Neurofilament Early rese
Slide 31: Infectious diseases pipeline
Infectious diseases pipeline Comprehensive pipeline addressing high unmet need across multiple indications Focus indications not exhaustive Hepatitis HIV Respiratory Tuberculosis Sepsis Others Respiratory flex Gastro flex HCV PSC HIV DUO II TB IGRA Prenosis (US) STI Panel BV/CV MPLX MPLX ePlex Respi
Slide 32: Oncology pipeline
Oncology pipeline Extensive offering across the disease continuum by leveraging multiple technologies not exhaustive Screening Diagnosis Therapy selection/ risk stratification Monitoring CxCa Digital AVENIO CGP Foundation Foundation Next screening Pathology IHC CDx (incl. HRD RUO on AlgoSuite IHC/IS
Slide 33: Recent breakthrough device designations (BDDs)
Recent breakthrough device designations (BDDs)* Continuing recognition of leading innovation by the US FDA Oncology Neurology Infectious diseases Others • FACT CDx (liquid biopsy assay): 70 • Elecysys® β-Amyloid and Elecsys® • cobas® EBV: EBV in transplant • Preeclampsia - Elecsys s-Flt and oncogene
Slide 34: Recent FDA PMA/BLA approvals
Recent FDA PMA/BLA* approvals We received >50% of overall FDA approved innovative IVD solutions in the last 5 years New FDA PMA/BLA approvals (Roche vs. competitors) 43 38 19 31 23 11 29 19 8 24 13 20 15 9 6 2019 2020 2021 2022 2023 Roche Competitors * PMA/BLA=Premarket Approval/Biologics License Ap
Slide 35: Serum Work Area Systems
Serum Work Area Systems The future of the Clinical Laboratory Benjamin Lilienfeld Lifecycle Leader Serum Work Area Systems
Slide 36: IVD and SWA market overview 2023
Core Lab IVD1 and SWA market overview 2023 Roche is a strong player in IVD and SWA2 IVD market 2023 SWA market 2023 Roche SWA CHF 7bn CHF 2bn Clinical chemistry Other IVD 25% 59% CHF 5bn Immunochemistry CHF SWA 39% CHF 68bn 41% 28bn 14% 11% 11% SWA market +7% +10% Roche Competitor 1 Competitor 2 SWA
Slide 37: Large installed base with significant growth in 2023
Core Lab Large installed base with significant growth in 2023 +3% SWA analytical units of which: cobas® pro / pure +77% +2% Lab SW Solutions +14% Preanalytics / Connectivity HE600 +12% BenchMark ULTRA/ +20% cobas® 5800/6800/8800 ULTRAPLUS +10% DP200/DP600 +29% +6% cobas® Liat 2023 Growth rates – fro
Slide 38: SWA placements hitting all time high in 2023
Core Lab SWA placements hitting all time high in 2023 cobas® pure integrated solutions cobas® pro integrated solutions Small to medium volume labs Medium to high volume labs >2,100 installations as of Dec 20231 >3,100 installations as of Dec 20231 +122% growth in installed base vs 20221 +60% growth
Slide 39: cobas ISE neo and cobas c703 analytical unit
Core Lab cobas® ISE neo and cobas® c703 analytical unit Introducing high-volume clinical chemistry and ISE testing to cobas® pro integrated solutions CE launch in Q2 2024 Strategic impact • Transition to fully standardized portfolio, streamlining operations and achieving cost efficiencies • Protect
Slide 40: Mass spectrometry: A powerful and largely underutilized technology
Core Lab Mass spectrometry: A powerful and largely underutilized technology1 Additional layers of information to address diverse patient cohorts Mass spectrometry technology and clinical situations benefits Mass • Ability to accurately measure spectrometry complex analytes • Higher sensitivity than
Slide 41: How does the mass spectrometry technology work?
Core Lab How does the mass spectrometry technology work? Sample preparation Liquid chromatography (LC) Mass spectrometry (MS) Data Processing Triple Ion Source Quadrupole Detector Chromatogram Result + + + Ionization Component Ion Fragment Ion selection fragmentation Ion selection Purification of Se
Slide 42: Reasons for current limited use of mass spectrometry
Core Lab Reasons for current limited use of mass spectrometry Current mass spectrometry setup Current mass spectrometry limitations High operational complexity, labor intensive lab- developed tests No integration, automation or standardization Expert training and education needed 66% of users find c
Slide 43: Introducing the future cobas Mass Spec solution
Introducing the future cobas® Mass Spec solution 43
Slide 44: The future cobas Mass Spec solution
Core Lab The future cobas® Mass Spec solution First fully integrated IVD platform for clinical mass spectrometry Seamless integration Full automation into routine testing from sample to result Clinical Chemistry Immunochemistry Mass Spectrometry Broad assay menu of Increased patient access to high m
Slide 45: Integrating mass spectrometry into the routine lab workflow
Core Lab Integrating mass spectrometry into the routine lab workflow Advancing from specialized to routine testing discipline Morphine-3 Lamotrigine Phenobarbital Phenytoin free Dihydrocodeine -glucuronide Gabapentin Codeine 24,25OH2 Vit D2 Cyclosporine A Carbam. epoxide Levetiracetam Phenytoin 6-Mo
Slide 46: The future cobas Mass Spectrometry solution
Core Lab The future cobas® Mass Spectrometry solution First fully integrated IVD platform for clinical mass spectrometry CE launch in Q4 2024 Market potential • Current total mass spectrometry market to be addressed: CHF 3bn1 • Expected 5-year CAGR for mass spectrometry market: +5%1 Strategic impact
Slide 47: Accu-Chek SmartGuide CGM solution
Accu-Chek SmartGuide CGM solution Jochen Berchtold Lifecycle Leader – Continuous monitoring
Slide 48: Diabetes worldwide
Near Patient Care Diabetes worldwide A global epidemic and strain to healthcare systems Roche customers ~537 million ~297 million ~149 million ~8 million Adults with diabetes1 … are diagnosed1 … receive care2 … are CGM3 users Global annual diabetes costs1 of roughly CHF 883bn 1.IDF Diabetes Atlas (2
Slide 49: CGM market and competitive position
Near Patient Care CGM market and competitive position Attractive market expected to double in size by 2030 CGM market size CGM users by therapy in 2024 (estimated) CHF bn Continuous subcutaneous insulin infusion (CSII) Diet & Lifestyle +13%* 1% 20 13% Oral antidiabetic drugs 16 (OAD) + insulin 19% 5
Slide 50: Accu-Chek SmartGuide CGM solution
Near Patient Care Accu-Chek SmartGuide CGM solution Enabling better decision-making for people with diabetes Accu-Chek SmartGuide CGM solution Improving diabetes management and care continuum • Data released at ATTD shows strong performance of Roche CGM solution • 14 days of reliable and accurate re
Slide 51: Accu-Chek SmartGuide CGM solution
Near Patient Care Accu-Chek SmartGuide CGM solution A CGM solution to address the unmet needs of people with diabetes Target population Value proposition Competitive advantage Enable patients to act Accu-Chek SmartGuide T1/T2 MDI, new to CGM before a problem occurs Predict app Aiming to support T1D
Slide 52: Address unmet medical needs with predictive algorithms
Near Patient Care Address unmet medical needs with predictive algorithms Not knowing where glucose is heading Night-time hypoglycemias often come unannounced “Knowing my trends [prediction] is a strong “It would help me to know hypos. Currently I do not message for me, as today I guess a lot.” feel
Slide 53: Accu-Chek SmartGuide Predict app
Near Patient Care Accu-Chek SmartGuide Predict app Glucose Predict aiming at 2-hour prediction empowering people with diabetes to be prepared and take action Glucose prediction app 53
Slide 54: Accu-Chek SmartGuide Predict app
Near Patient Care Accu-Chek SmartGuide Predict app Night Low Predict aimed at empowering people with diabetes to act before a problem even occurs Night Low Predict app 1. Preventive notifications for high risk nights can be set. Accu-Chek SmartGuide sensor is pre CE mark. Not available for sale 54
Slide 55: Roche CGM market expansion and device evolution
Near Patient Care Roche CGM market expansion and device evolution Serving 19 million people with diabetes with unmet medical need Launch focus Segment expansion Therapy segments Multiple Continuous Subcutaneous Fixed Oral Antidiabetic Drugs Daily Injections (MDI) Insulin (CSII/ Pump) Insulin (FI) (O
Slide 56: Rapid response with Point of Care solutions
Rapid response with Point of Care solutions Ildikó Amann-Zalán Head of Research & Development Roche Diagnostics Solutions
Slide 57: Decentralized care: Path for continued growth
Near Patient Care Decentralized care: Path for continued growth How we will get there Cardiometabolic Infectious diseases Digital connectivity Home Pharmacy General practitioners & specialists Emergency room & intensive care unit 57
Slide 58: Decentralized care: Path to sustained growth
Near Patient Care Decentralized care: Path to sustained growth Driving customer and patient value through a combination of performance and proximity Cardiometabolic cobas® sense - focus on CM and Sepsis Infectious diseases cobas® liat - focus on respiratory, STI and HAI Digital connectivity Accu-Che
Slide 59: cobas sense
Near Patient Care cobas sense Bringing lab equivalent performance to the Point of Care cobas sense Market opportunity • Cardiovascular diseases (CVDs) are the leading cause of death globally • An estimated 15 million people died from CVDs in 2020, representing 31% of all global deaths • CHF >1bn tot
Slide 60: cobas liat system
Near Patient Care cobas® liat system mPoC testing shows attractive growth opportunities Roche on market assays 2023 mPOC market cobas® SARS-CoV-2 assay • Market size CHF 3bn cobas® SARS-CoV-2 & Influenza A/B assay • Fast growing market: grew 6-fold cobas® Influenza A/B & RSV assay from 2019 to 2023
Slide 61: Molecular PoC respiratory portfolio expansion
Near Patient Care Molecular PoC respiratory portfolio expansion cobas® liat helps guiding clinical response for infection management and control cobas® liat SARS-CoV-2, Flu A/B & RSV1 submitted for EUA2 • Detection and differentiation of four respiratory targets in one test: o SARS-CoV-2, RSV, Influ
Slide 62: Summary
Near Patient Care Summary Cohesive PoC strategy The Point of Care strategy is centered around the diverse needs of different customers We focus on cardiometabolic and infectious diseases We aim to deliver lab-like performance and reliable results We invest to become a leader in decentralized testing
Slide 63: Upcoming molecular launches
Upcoming molecular launches Nico Michel Lifecycle Leader Infectious Diseases - Molecular Lab
Slide 64: Molecular Lab launches and innovations
Molecular Lab Molecular Lab launches and innovations Streamline molecular testing and deliver innovation to growing installed base across continuum of care High-volume, fully Point of care automated IVD testing Open molecular Syndromic panel solutions testing Routine efficiency and automation Versat
Slide 65: cobas 6800/8800 version 2.0
Molecular Lab cobas® 6800/8800 version 2.0 Retrofittable upgrade with increased testing flexibility, higher throughput and greater automation CE launch in Differentiation Q4 2024 • Increased flexibility and broader menu consolidation: from 3 to 6 assays per run, customizable QC reduces run costs • ~
Slide 66: cobas Malaria test for cobas 5800/6800/8800 Systems
Molecular Lab cobas® Malaria test for cobas® 5800*/6800/8800 Systems First molecular donor screening test to protect the blood supply from malaria infection Unmet medical need and medical value • Transfusion-transmitted malaria infection can cause serious complications and death in recipients • Incr
Slide 67: cobas eplex system introduction & product improvements
Molecular Lab cobas® eplex system introduction & product improvements 7 years of continuous input & 12 months of direct customer engagement through interviews & concept modeling Unlocking the power of GenMark • Driving stabilization and scale of manufacturing • Furthering integration to take advanta
Slide 68: cobas eplex - gastrointestinal infection panel
Molecular Lab cobas® eplex - gastrointestinal infection panel Simultaneously test & detect most commonly viral, bacterial & parasitic pathogens associated with gastroenteritis GI Panel: 19 reported targets Key features and benefits Bacterial Workflow and Pathogens Software benefits integration solut
Slide 69: Respiratory projected to remain one of the biggest revenue drivers
Molecular Lab Respiratory projected to remain one of the biggest revenue drivers for Molecular diagnostics Molecular diagnostics market size (in CHF bn) Respiratory infection Molecular diagnostics market size transition from • Respiratory projected to remain one of the biggest revenue pandemic to en
Slide 70: Complementing upper respiratory testing offering
Molecular Lab Complementing upper respiratory testing offering High-quality solutions for every setting GOLD STANDARD PCR TESTING Versatile & Routine Comprehensive Targeted & near specific efficiency & fast patient Elecsys® for immunoassays cobas® x800 Systems cobas® ePlex® cobas® liat® system Elecs
Slide 71: cobas Respiratory flex for use on cobas x800 Systems
Molecular Lab cobas® Respiratory flex for use on cobas® x800 Systems Flexible syndromic testing empowered by Roche’s novel and proprietary TAGS technology Empowered by TAGS 5 channels = up to 15 targets Differentiation high • Qualitative detection and differentiation of 12* respiratory viruses in na
Slide 72: Sequencing Update
Sequencing Update Palani Kumaresan Global Head Roche Diagnostics Solutions
Slide 73: Roche sequencing offering
Molecular Lab Roche sequencing offering An end-to-end ecosystem that meets the needs of translational research and clinical labs End to End workflow: Enabling faster, more flexible, and cheaper sequencing at scale Library Prep & Nucleic Acid Sequencing Sample Target 2o Analysis 3o Analysis Extractio
Slide 74: Nanopore sequencing
Molecular Lab Nanopore sequencing 4th generation single molecule sequencing chemistry Xpandomer chemistry Key benefits • Improved signal-to-noise enables high accuracy • Real-time data generation and analysis allows for: • Flexible run conditions • Versatile throughput • Fast turn around times • Ove
Slide 75: Nanopore sequencing
Molecular Lab Nanopore sequencing Scalable and flexible sequencing chip design Novel chip design Key benefits • Enables 8 million microwells to sequence individual expandomers in parallel • Optical-free / semiconductor-based signal capture allows for: • Simplified instrument • Attractive cost struct
Slide 76: Pathology Lab Update
Pathology Lab Update Jill German Head of Pathology Lab Customer Service Area
Slide 77: Roche Diagnostics patients and counting
33.7 million 2023 38.4 million Roche Diagnostics so 38 m i Wier patients and counting
Slide 78: Roche Pathology Lab global market leader
Pathology Lab Roche Pathology Lab global market leader Well positioned to drive digitalization of the Pathology Lab Pre-analytics Pathology Lab Market1 • 2023 market size CHF4.8bn Workflow management, integration and • CAGR estimated at 8% connectivity Primary staining Advanced position in Tissue Di
Slide 79: Roche Digital Pathology provides end-to-end solutions
Pathology Lab Roche Digital Pathology provides end-to-end solutions Three key elements that come together to enable a seamless solution for pathologists Slide scanning Pathologist interface Image analysis VENTANA® slide scanners Open Environment for Algorithm navify® Digital Pathology deployment ● T
Slide 80: Accelerating adoption of our DP solution
Pathology Lab Accelerating adoption of our DP solution IVD claim on the slide scanner and strategic partnerships to enhance solution attractiveness Regulatory strategy to building a foundation Collaboration with PathAI to build CDx of cleared (IVD) components algorithms for Roche DP solution Primary
Slide 81: Continuing to expand the portfolio
Pathology Lab Continuing to expand the portfolio Strong internal pipeline + open environment ecosystem to establish a market leading DP solution navify Digital Primary PHC/CDx PR Pathology Diagnosis Pipeline HER2 Dual ISH (nDP 2.x) PD-L1 (SP142) Breast Product Offering ER MPx and Algo Pipeline HER2
Slide 82: Neurology Strategy & Pipeline
Neurology Strategy & Pipeline Olivier Gillieron Lifecycle Leader Cardiometabolic and Neurology
Slide 83: Ageing population and neurological conditions
Neurology Ageing population and neurological conditions Neurological conditions, including Alzheimer’s Disease, constitute significant health and socioeconomic burden Ageing population Economic burden Health threat World population ≥65 years old Economic burden* of AD and related Predicted global ma
Slide 84: Trends in the neurology space
Neurology Trends in the neurology space Advances in science and technology will transform clinical care pathways Digital health Drug delivery solutions technology Biomarkers Disease diagnostics & modifying imaging therapies Personalized Virtual care medicine/gene telehealth & remote therapy monitori
Slide 85: Roche's value proposition for neurology solutions in Diagnostics
Neurology Roche’s value proposition for neurology solutions in Diagnostics Roche is well positioned to make a positive impact on clinical care pathways Neurology vision Integrated solutions along patient journey Biomarker discovery IVD solutions Market leadership Early research collaborations Clinic
Slide 86: Biomarker discovery and development
Neurology Biomarker discovery and development Strong partnerships with Pharma and Academia enable us to be at the forefront of science Drive biomarker discovery and Validate in NeuroToolKit (NTK) Inform clinical trial design and develop robust prototype assays and accelerate development develop diag
Slide 87: Integrated solutions along patient journey
Neurology Integrated solutions along patient journey Anchor in neurodegenerative & aid in diagnosis to extend along patient journey and across diseases Screen & Triage Diagnose Treat & Monitor Cognitive Early detection Differential Pathology Therapy (DMT) initiation DMT safety & efficiency Continuou
Slide 88: pTau217 test complements Alzheimer's Disease offering
Neurology pTau 217 test complements Alzheimer‘s Disease offering Evidence from global trial will be key to implement solutions in clinical practice Elecsys CSF ratios Elecsys Amyloid Plasma Panel Elecsys pTau217 test2 • tTau, pTau181 & Abeta42 • Biomarkers pTau181 & ApoE4p • Biomarker pTau217 • NPV
Slide 89: NfL in Multiple Sclerosis
Neurology NfL in Multiple Sclerosis Aids in detection of disease activity to guide treatment decisions Role of NfL along patient journey for MS (disease burden ~3 million people1,2) Treatment selection Disease monitoring Treatment selection & Treatment & disease Patient management & initiation monit
Slide 90: Roche is well positioned to drive access to our neurology innovations
Neurology Roche is well positioned to drive access to our neurology innovations Build on our commercial presence around the world #1 #1 Attractive Diagnostics business case in Neurology In vitro Diagnostics In Neurology for Roche Pharma Differentiation in Core Lab and beyond >47,000 >150 Integrated
Slide 91: Doing now what patients need next
Doing now what patients need next